TGTX earnings call for the period ending June 30, 2020.
News & Analysis: TG Therapeutics
The development-stage company appears to be on the path to commercial operations.
TGTX earnings call for the period ending December 31, 2019.
Acceleron Pharma, Novavax, and TG Therapeutics are all on the cusp of hitting major milestones.
These pharma stocks have gone in different directions in the last year, but both hold promise for forward-thinking investors.
These two small-cap biopharmas have promising early-stage drug candidates that could take them far if all goes according to plan.
Two triple-combination therapies delivered impressive results in early-stage studies, which propelled the stock to a 170% gain in 2019.
Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies.
A triple-combination therapy from the company triggered responses in 100% of patients with difficult-to-treat blood cancers.
TGTX earnings call for the period ending September 30, 2019.